Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of Vicagrel vs Clopidogrel in Healthy CYP2C19 Normal Metabolizers
NCT07067775Phase 1Completed
- Sponsor
- Jiangsu Vcare PharmaTech Co., Ltd.
- Start
- Aug 2025
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vicagrel in acute coronary syndrome (ACS) (2 arms), sponsored by Jiangsu Vcare PharmaTech Co., Ltd. Primary endpoints: Area Under the Curve From Time Zero to Last Quantifiable Concentration and Maximum Plasma Concentration. Started Aug 2025; status: completed.
02
Drugs
vicagrel
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT07067775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07067775.